Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Abderrahmane Mami Hospital
With
Eshmoun Clinical Research Center
Datametrix
Interventional, Multicentric, Randomized Controlled Study in Two Parallel Groups of 530 Healthcare Professionals working in the Intensive Care Unit Exposed to Risk of COVID19 Infection Taking Hydroxychloroquine (HCQ) (200 mg/day) VS Placebo
Age
18–65
Sex
ALL
Healthy volunteers
Accepted
You may be eligible if
Diagnosis of COVID-19 (-)
Works in a medical intensive care unit exposed to COVID-19 infection
18 years old \< age \< 65 years old
Having given written consent for their participation in the study.
You may not be if
Diagnosis of COVID-19+
Retinopathies,
Hydroxychloroquine or other prophylactic treatments for VIDOC19 within one month prior to inclusion and throughout the study.
Hypersensitivity to chloroquine or hydroxychloroquine or 4-aminoquinolines or any of the other components of this drug,
Contraindication to prophylactic use of chloroquine, e.g. liver failure, known epilepsy, creatinine clearance \< 30 ml/min.
Inability to be monitored during the trial period
Pregnancy and breastfeeding
Psoriasis
Clareo Health | Assessment of the Efficacy and Safety of (HCQ) as a Prophylaxis for COVID19 for Health Professionals
